Human EGFR Antibody - Cetuximab biosimilar

Anti-human EGFR - Cetuximab biosimilar - CAS #205923-56-4

Anti-hEGFR-hIgG1 is a biosimilar antibody of Cetuximab, a chimeric human/mouse IgG1 antibody targeting the epidermal growth factor receptor (EGFR). EGFR is a cell surface receptor overexpressed in many types of cancer promoting cell proliferation, survival, and angiogenesis. Cetuximab is FDA-approved for the treatment of metastatic colorectal cancer and metastatic squamous cell carcinoma of the head and neck.

 More details

Anti-hEGFR-hIgG1 comprises the variable region of Cetuximab and the IgG1 constant region of Cetuximab for high effector functions.

Cetuximab inhibits the binding of epidermal growth factor (EGF) or transforming growth factor-α (TGF-α), the natural ligands of the EGFR, and induces receptor internalization and degradation. Due to its IgG1 constant region, Cetuximab also induces cell death through antibody-dependent cell-mediated cytotoxicity (ADCC).

This antibody can be used for screening and neutralization assays to block EGFR signaling. It can also be used together with the human EGFR-expressing Raji target cell line for ADCC Fc effector studies either with peripheral blood mononuclear cells, natural killer (NK) cells, or T cell-derived Jurkat reporter cells (see figure).

Key features

• Each lot is functionally tested and validated
• The complete sequence of the antibody construct has been verified
• Absence of endotoxins determined by the EndotoxDetect assay

More isotypes of this antibody are available and can be used for comparison of biological activities such as ADCC (see in the 'upon request' section).

InvivoGen’s products are for research use only, and not for clinical or veterinary use.

Figures

Comparison of ADCC potency for native and engineered anti-human EGFR antibody isotypes. Raji-hEGFR cells were incubated with gradient concentrations of Anti-hEGFR or Anti-β-galactosidase (β-Gal) mAbs for 1 hour. Jurkat-Lucia™ NFAT-CD16 effector cells were then co-incubated with target cells for 6 hours. NFAT activation, reflecting the induced ADCC response, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™. Percentages of the maximal response normalized to the IgG1 isotype are shown.

Specifications

Application: Flow cytometry, ELISA, Fc interaction studies, ADCC

Isotype:  Human IgG1, kappa

Recommended isotype control: Human IgG1

Target: Human EGFR

Species reactivity: Human

Clone: Cetuximab, C225

Cas number: 205923-56-4

Sterility: 0.2 µm filtration

Source: CHO cells 

Production: Animal-free

Purification: Protein A

Molecular weight: 145.5 kDa

Physical form: Lyophilized

Formulation buffer: Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Preservative: Azide-free

Reconstitution buffer: Sterile water (not provided)

Purity: ≥ 95 %

Quality control: Each lot is functionally tested and validated

Contents

Anti-hEGFR-hIgG1 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:

• hegfr-mab1: 100 µg
• hegfr-mab1-1: 1 mg

Product is shipped at room temperature

 Upon receipt, store at -20°C.

Tags: buy Cetuximab (anti-EGFR) | Cetuximab (anti-EGFR) supplier | purchase Cetuximab (anti-EGFR) | Cetuximab (anti-EGFR) cost | Cetuximab (anti-EGFR) manufacturer | order Cetuximab (anti-EGFR) | Cetuximab (anti-EGFR) distributor

Details

Cetuximab background

Cetuximab (ERBITUX®) is a chimeric mouse/human IgG1 monoclonal antibody (mAb) that specifically targets the epidermal growth factor receptor (EGFR). EGFR is a cell surface receptor overexpressed in many types of cancer, promoting cancer cell proliferation, survival, and angiogenesis, subsequently leading to tumor growth and metastasis [1].

Cetuximab binds to the extracellular domain III of EGFR, blocking ligand interaction and preventing receptor dimerization and activation triggered by its natural ligands, such as epidermal growth factor (EGF), transforming growth factor-α (TGF-α), amphiregulin, and heparin-binding EGF (HB-EGF) [2]. Due to its IgG1 constant region, it also induces receptor internalization, degradation, and cell death through antibody-dependent cell-mediated cytotoxicity (ADCC) [3-4]. Cetuximab is FDA-approved for a variety of cancer types, such as squamous cell carcinoma of the head and neck (SCCHN) and colorectal cancer [5].

References:

1. Vincenzi B. et al., 2010. Cetuximab: from bench to bedside. Curr Cancer Drug Targets. 10(1):80-95.
2. Li S, Schmitz KR, et al., 2005. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 7(4):301-11.
3. Kurai J. et al., 2007. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 3(5):1552-61.
4. Kimura H. et al., 2007. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 98(8):1275-80.
5. FDA website accessed in Dec 2024: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125084s273lbl.pdf